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Restricted processing of CD16a/Fc γ receptor IIIa N-glycans from
primary human NK cells impacts structure and function
Abstract
CD16a/Fc γ receptor IIIa is the most abundant antibody Fc receptor expressed on human natural killer (NK)
cells and activates a protective cytotoxic response following engagement with antibody clustered on the
surface of a pathogen or diseased tissue. Therapeutic monoclonal antibodies (mAbs) with greater Fc-mediated
affinity for CD16a show superior therapeutic outcome; however, one significant factor that promotes
antibody–CD16a interactions, the asparagine-linked carbohydrates (N-glycans), remains undefined. Here, we
purified CD16a from the primary NK cells of three donors and identified a large proportion of hybrid (22%)
and oligomannose N-glycans (23%). These proportions indicated restricted N-glycan processing and were
unlike those of the recombinant CD16a forms, which have predominantly complex-type N-glycans (82%).
Tethering recombinant CD16a to the membrane by including the transmembrane and intracellular domains
and via coexpression with the Fc ϵ receptor γ–chain in HEK293F cells was expected to produce N-glycoforms
similar to NK cell–derived CD16a but yielded N-glycoforms different from NK cell–derived CD16a and
recombinant soluble CD16a. Of note, these differences in CD16a N-glycan composition affected antibody
binding: CD16a with oligomannose N-glycans bound IgG1 Fc with 12-fold greater affinity than did CD16a
having primarily complex-type and highly branched N-glycans. The changes in binding activity mirrored
changes in NMR spectra of the two CD16a glycoforms, indicating that CD16a glycan composition also affects
the glycoprotein's structure. These results indicated that CD16a from primary human NK cells is
compositionally, and likely also functionally, distinct from commonly used recombinant forms. Furthermore,
our study provides critical evidence that cell lineage determines CD16a N-glycan composition and antibody-
binding affinity.
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CD16a/Fc  receptor IIIa is the most abundant antibody Fc
receptor expressed on human natural killer (NK) cells and acti-
vates aprotective cytotoxic response following engagementwith
antibody clustered on the surface of a pathogen or diseased tis-
sue. Therapeutic monoclonal antibodies (mAbs) with greater
Fc-mediated affinity for CD16a show superior therapeutic out-
come; however, one significant factor that promotes antibody–
CD16a interactions, the asparagine-linked carbohydrates
(N-glycans), remains undefined. Here, we purified CD16a from
the primary NK cells of three donors and identified a large pro-
portion of hybrid (22%) and oligomannose N-glycans (23%).
These proportions indicated restrictedN-glycan processing and
were unlike those of the recombinant CD16a forms, which
have predominantly complex-type N-glycans (82%). Tethering
recombinant CD16a to the membrane by including the trans-
membrane and intracellular domains and via coexpression with
the Fc  receptor –chain in HEK293F cells was expected to
produce N-glycoforms similar to NK cell–derived CD16a but
yielded N-glycoforms different from NK cell–derived CD16a
and recombinant soluble CD16a. Of note, these differences in
CD16aN-glycan composition affected antibody binding: CD16a
with oligomannose N-glycans bound IgG1 Fc with 12-fold
greater affinity than did CD16a having primarily complex-type
and highly branchedN-glycans. The changes in binding activity
mirrored changes inNMRspectra of the twoCD16a glycoforms,
indicating that CD16a glycan composition also affects the glyc-
oprotein’s structure. These results indicated that CD16a from
primaryhumanNKcells is compositionally, and likely also func-
tionally, distinct from commonly used recombinant forms.
Furthermore, our study provides critical evidence that cell line-
age determines CD16a N-glycan composition and antibody-
binding affinity.
Antibodies activate a diverse set of protective responses fol-
lowing the recognition of a previously-encountered epitope.
Therapeutic monoclonal antibodies (mAbs) circumvent prior
exposure to induce a protective response against diseased tissue
by eliciting the same protective mechanisms, including anti-
body-dependent cell-mediated cytotoxicity (ADCC)3 through
binding Fc  receptors (FcRs), and represent a major drug
class worth tens of billions of dollars each year in global sales.
mAbs are predominantly built from immunoglobulin G (IgG),
and a large proportion bind FcRs expressed on a range of leu-
kocytes to initiate target destruction. However, very little is
known about the composition of FcRs from native leukocytes
and how this composition affects IgG binding and thus treat-
ment efficacy.
ADCC is predominantly performed by natural killer (NK)
cells (1), and cytolytic lymphocytes present as 1–6% of circu-
lating leukocytes (2, 3) that express FcRIIIa/CD16a as the pre-
dominant FcR. The activating role of CD16a in ADCC by NK
cells is well-established (1). Indeed, investigations of rituximab,
trastuzumab, and cetuximab therapeutics demonstrated the
importance of CD16a on NK cells for success (4).
Improved therapeutic mAb efficacy can be achieved by
enhancing the mAb–CD16a interaction. In vitro binding stud-
ies demonstrated the less common CD16a Val-158 allotype
binds IgG1 with5-fold greater affinity compared with CD16a
Phe-158 (5). Furthermore, increased binding leads to an
increased NK cell response and increased ADCC (6–9). Cur-
rent advances inmAb therapy are targeting optimization of NK
cell ADCC activity by Fc glycoengineering to improve CD16a
binding (4). These efforts include targeted modifications to the
asparagine-linked carbohydrate (N-glycan) attached to Asn-
297 of the IgG1 heavy chain (9, 11). A glycoengineered mAb
performed better in the clinic when compared with a non-op-
timized version (4, 12).
N-Glycans contribute to protein function and are targets for
new therapies or enhancing existing therapies. N-Glycan pro-
cessing occurs during protein secretion. The types and extent of
modifications are not template-driven; thus, it is not currently
possible to predict N-glycan composition from DNA sequence
information. Following the en bloc transfer of a 14-residue pre-
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cursor N-glycan as directed by the presence of an NX(S/T)
sequon, whereX is any residue except proline, the glycoprotein
associates with protein folding-specific chaperones, and if
properly folded, it continues through the ER and Golgi-medi-
ated secretory pathway to encounter remodeling glycosyl-
hydrolase and glycosyltransferase enzymes (Fig. 1). Although
many factors contributing to N-glycan composition on any
given protein remain undefined, it is generally believed that
modifying enzyme expression, protein structure, and the pres-
ence or absence of a membrane anchor affectN-glycan compo-
sition in the secreted protein (13). N-Glycans that experience
minimal processing emerge from the cell as oligomannose
forms (Fig. 1B). More highly processed N-glycans may also
include hybrid forms and the predominant complex types
found on cell surfaces and circulatory serum proteins. In addi-
tion to folding, N-glycans promote secretion, protect against
proteolysis, reduce antigenicity, extend serum half-life, and
contribute specific epitopes for receptor binding as well as
impact protein structure and function (14–16).
The CD16a sequence encodes five N-glycosylation sites,
although little is known about either theN-glycan composition
or how CD16a N-glycans impact function. Edberg and Kim-
berly (17) report that NK cell CD16a contained a high degree of
oligomannose-type N-glycans using immobilized lectin chro-
matography and found little evidence for complex or hybrid
types. This characterization was in stark contrast to later mass
spectrometry-based reports on the glycosylation of recombi-
nant CD16A, which identified predominantly complex types
with low percentages (2–5%) of oligomannose N-glycans (18–
21). However, these recombinant expressions did not include
the membrane anchor and intracellular domains nor the coex-
pressed Fc  receptor - or CD3 -chains that may influence
N-glycan processing. It is well-known that N-glycan composi-
tion can influence protein function (15, 22–24), with some evi-
dence indicating composition might affect the antibody-bind-
ing function of CD16a (21). Thus, the in vitro analyses of
monoclonal antibody binding by CD16a should include proper
N-glycoforms for representative results. At this point, there has
not been a report on the high-resolutionN-glycan composition
of CD16a from primary human leukocytes.
Access to a sufficient quantity of primary human tissue rep-
resents a significant barrier to high-resolution composition
studies because CD16a is expressed by a limited subset of leu-
kocytes, including natural killer cells and CD16a monocytes
that constitute 1–6 and 0.4–2.4% of circulating leukocytes,
respectively (3, 25).We predict that it would require asmuch as
1.25 liters of human blood to recover a minimum of 100 106
natural killer cells and 1 g of CD16a from a single donor to
provide sufficient material for characterization. It is untenable
to harvest one-quarter or more of a donor’s blood volume for
obvious reasons. The adoption of apheresis systems by blood
donation centers to collect plasma, platelets, and other blood
components provides a valuable source of viable primary
human lymphocytes from peripheral blood through leukocyte
reduction system (LRS) filters that are normally discarded fol-
lowing donation (26). In this study, we describe a method to
purify CD16a from primary human NK cells from a single
donor to analyze N-glycan composition.
Results
NK cell isolation and CD16 purification
Light scattering of isolated NK cells combined with CD56
and CD16 staining assessed by flow cytometry revealed 90%
cell purity, 87% viability, and a high degree of CD16 expres-
sion (Fig. 2 and Fig. S1). A blot of NK cell lysate probed with an
anti-CD16 antibody showed a band from 53 to 59 kDa (Fig. 2C).
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Figure 1. Membrane-anchored CD16a binds IgG antibodies. A, CD16a
(orange ribbon) contains five potential N-glycosylation sites in the extracellu-
lar domains (orange spheres). B, N-glycan processing occurs in the ER and
Golgi following transfer of a large glycan en bloc to the protein and produces
oligomannose, hybrid, and complex-typeN-glycans. Individual carbohydrate
residues are colored according to the SNFG convention (14).
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Figure2. RepresentativeNKcell isolationandCD16apurification.A, light
scattering; B, double-antibody staining of negatively-selected NK cells. Iso-
type and negative-staining controls are shown in Fig. S1. C, anti-CD16 West-
ern blot of PNGase F-digested CD16a shows an increase inmobility following
N-glycan removal. D, anti-CD16 Western blot of CD16a purification from an
NK cell lysate compared with recombinant CD16a truncated at the trans-
membrane domain (HEK293F).
N-Glycans fromNK cell CD16a
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Despite differences in CD16 staining intensity measured from
more than a dozen donors, NK cell lysate repeatedly showed
indistinguishable CD16 migration characteristics (data not
shown). The mobility of the NK cell CD16 band in an SDS-
PAGE experiment increased following digestion with PNGase
F, an enzyme that specifically removesN-glycans. However, the
resulting two bands at33 kDa are still larger than expected for
the 27-kDa CD16a polypeptide (Fig. 2C). This treatment indi-
cates that N-glycans retard CD16 mobility in a polyacrylamide
gel. The CD16 identified here is consistent with CD16 from
multiple previous reports based on migration in SDS-PAGE
(27–30).
A monoclonal anti-CD16 mouse IgG1 antibody, 3G8 (31), is
widely used for flow cytometry but not for Western blotting
applications because CD16 denaturation destroys the epitope
(data not shown). Thus, 3G8 is a good candidate to precipitate
folded and processed CD16 from cell lysates at a preparative
scale. Our purification scheme first lyses NK cells in detergent,
followed by incubation with protein G resin to remove IgG that
may obscure theCD16 epitope recognized by the 3G8 antibody,
adsorption to a 3G8-agarose resin, extensivewashing to remove
material that weakly interacts with the resin, and finally elution
with 45:55:0.1 water/acetonitrile/TFA (Fig. S2). This procedure
showed clear depletion of CD16 from the NK cell lysate and
enrichment in the elution fraction with recovery of 1 g of
CD16/donor (Fig. 2D).
CD16a validationwith ESI-MS/MS
The observed mobility of CD16 from primary human NK
cells in SDS-polyacrylamide gels is similar to previous reports
and likely represents similar material, although peptide
sequencing or other comparable techniques were not previ-
ously applied for validation. Thus, we applied high-resolution
peptide sequencing to verify the immunoprecipitated material.
Purified and trypsin-digested CD16a from a single donor’s
NK cells generated multiple polypeptide fragments in an
HPLC(C18)-ESI-MS/MS experiment that fit with high confi-
dence to 47% of the CD16a sequence (Fig. 3). One peptide
revealed this donor expressed the predominantCD16a Phe-158
allele (Fig. 3D). The donor allotype was also confirmed by
cDNA sequencing (data not shown). This analysis did not
detect peptides from other proteins nor did it detect peptides
containing predicted CD16a N-glycosylation sites, transmem-
brane regions, or intracellular regions; however, the observed
peptides were enough to confirm CD16a identity. It is possible
that the immunoprecipitated material includes low levels of
contaminating proteins. To address this potential shortcoming,
we analyzed PNGase F-treated peptides from a single donor
using HPLC(C18)-ESI-MS/MS. This sample contained the Fc 
receptor -chain and the ubiquitous contaminant keratin from
humanhair and skin cells. Again, CD16a accounted for amajor-
ity of the identified peptides. Surprisingly, human actin and
myosin coeluted with CD16a, as well as trace amounts of tryp-
sin and the IgG1 heavy chain. With the exception of the IgG1
heavy chain that leached from the immunoprecipitation col-
umn, none of the identified proteins were N-glycoproteins.
These results indicate that the PNGase F treatment of the elu-
tion fraction will produce only CD16aN-glycans fromNK cells
if the immunoprecipitation antibody is treated to remove
N-glycans prior to immobilization.
N-Glycan analysis of CD16a from primary humanNK cells
We isolated peripheral NK cells from three male donors
ranging in age from 66 to 78 to characterize N-glycan compo-
sition; blood remaining in the LRS filter after apheresis pro-
vided geneticmaterial to determine the donor’s CD16a allotype
(Table 1 and Figs. S3 and S4). Following cell lysis, CD16a immu-
noprecipitation utilized EndoS-treated 3G8 antibody to elimi-
nate potential contaminationwith antibodyN-glycans (Fig. S5).
Analysis of procainamide-modified CD16a N-glycans by
hydrophilic interaction liquid chromatography (HILIC)-ESI-
MS showed a strong correlation betweenN-glycan elution time
andN-glycan mass (Fig. 4). We identified 33, 27, and 19 CD16a
N-glycans from donors 1–3, respectively, with an average mass
error of 0.0010 Da for the three datasets (supporting Spread-
sheet). The CD16a glycans contained minimally processed
forms, including a high percentage of oligomannose (23%) and
hybrid types (22%; Fig. 5). Of the remaining complex-type
N-glycans (55%), biantennary forms comprised more than half
of the complex-type species (51%). CD16a N-glycan fucosyla-
tion proved pervasive with 63% of the total and 89% of the
complex-typeN-glycans containing this modification (Fig. 5B).
CD16aN-glycans also revealed a high degree of sialylation with
100% of the hybrid and 78% of the complex-type forms display-
ing at least one N-acetylneuraminic acid residue (Fig. 5C).
Analysis of the individual glycoforms corresponding to the
10 most intense N-glycan species identified by MS showed
complex-type, core-fucosylated, and sialylated biantennary
N-glycans produced the two strongest signals in spectra of
CD16a N-glycans from all three donors (Fig. 6). However, the
next eight most intense ion species from each donor were pre-
dominantly hybrid forms (13/24) with comparable levels of
complex-type (6) and oligomannose (5) forms, includingMan9
(2), Man6 (2), and Man5 (1). This prevalence of N-glycan spe-
cieswith restricted processing in the three datasets is surprising
given the reports of N-glycans from recombinant CD16a that
are primarily of complex type with a high degree of branching
(21).
N-Glycan analysis of recombinant CD16a fromHEK293 cells
It is possible that CD16a N-glycans isolated from NK cells
differ from recombinant CD16a N-glycans because the soluble
recombinant fragment lacks the membrane anchor and experi-
ences a different environment during secretion, or thatNK cells
produce a different mixture of glycan-modifying enzymes, or a
combination of both possibilities. We expressed CD16a in
HEK293F cells to assess the impact of the transmembrane and
intracellular domains on N-glycan composition using two
forms: soluble recombinant CD16a that contains the two extra-
cellular antibody-binding domains (srCD16a) and full-length
recombinant CD16a containing the complete CD16a ORF,
including the signal peptide, coexpressed with the Fc  receptor
-chain (frCD16a). It is important to note that recombinant
expression of frCD16a requires coexpression with the Fc 
receptor -chain or CD3 -chain to achieve cell-surface local-
ization (data not shown) (32).
N-Glycans fromNK cell CD16a
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Migration in SDS-PAGE of srCD16a (28–46 kDa) and
frCD16a (38–43 and 47–59 kDa) showedmuch broadermigra-
tion distributions thanCD16a fromNK cells (53–59 kDa), indi-
cating a greater degree of heterogeneity for the recombinant
forms (Fig. S6). We identified 122 and 86 individual procain-
amide-derivatized srCD16a and frCD16a N-glycans, respec-
tively, with an average mass error of 0.0016 Da (Fig. S7). Pre-
dominant N-glycans species from srCD16a and frCD16a were
of a complex-type (82 and 73%, respectively) with low levels of
oligomannose forms (5 and 9%, respectively), which stands in
Table 1
NK cell donor information
Donor 1 Donor 2 Donor 3
Year of birth 1947 1951 1939
Sex M M M
ABO group A A A
Rh(D)   
CD16a allotype V/F V/V V/F
Collection date 5/31/17 5/18/17 5/18/17
NK cell count (106) 206 50 113
NK cell viability 93% 83% 86%
CD56 in NK cell preparation 83.8% 94.1% 95.6%
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Figure 3. ESI-MS/MSanalysis identifies only CD16a following immunoprecipitation fromNKcells.A,peptides identified are shownwith a blue barbelow
theCD16a sequence. Expected trypsin cleavage sites are indicatedwith a vertical line, andN-glycosylation sites are denotedwith a red “N.” B–D,MS/MS spectra
of select peptides.
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marked contrast to NK cell CD16a (Fig. 5 and supporting
Spreadsheet). Furthermore, the complex types showed much
greater representation of tri- and tetra-antennary forms than
NK cell CD16a. Fucosylation of all srCD16a and frCD16a spe-
cies was comparable (71%), and both were greater than NK
cell CD16a (63%). Furthermore, fewer srCD16a and frCD16a
N-glycans contained N-acetylneuraminic acid when com-
pared with NK cell CD16a. This characterization of srCD16a
is highly comparable with expressions in NS0 cells (19) with
6% oligomannose (Man4–6) or BHK cells with no oligoman-
nose (33).
Closer inspection of N-glycan species revealed stark differ-
ences between the recombinant forms. Themost intenseN-gly-
can signals from srCD16a included a majority of complex-type
forms (9/10) in contrast to frCD16a (6/10) that included a sig-
nificant contribution from oligomannose forms (4/10; includ-
ing Man9, Man8, Man7, andMan5; Fig. 6). Furthermore, com-
plex-type glycans from frCD16a showed a low level of hexose
incorporation (2/6; likely galactose) in contrast to srCD16a
with a very high degree of branching (7/9 w/3 branches) and
hexose incorporation (8/9). By these measures, the CD16a
membrane anchor and Fc  receptor -chain coexpression
resulted in the synthesis of a higher degree of hybrid and oligo-
mannose N-glycans, but neither the soluble nor membrane-
anchored recombinant CD16a forms recapitulated the N-gly-
can species found onNKcell CD16a. It is important to note that
by using a detergent to solubilize the cell membrane, folded
but incompletely-processed CD16a residing in the ER and
the Golgi at the moment of cell lysis will be purified in addi-
tion to CD16a from the cell surface. However, frCD16a was
extracted using the same technique as NK cell CD16a, and
thus a direct comparison between these two sources is justi-
fiable. Furthermore, the impact of incompletely-processed
CD16a from the ER and Golgi cannot alone account for the
increased prevalence of hybrid forms when compared with
frCD16a or srCD16a because 100% of the NK cell CD16a
hybrid glycoforms are sialylated, a hallmark of late-stage
N-glycan processing.
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Oligomannose N-glycans increase receptor affinity
The difference between CD16a N-glycan species from pri-
mary NK cells and recombinant expression systems appears
compelling because both cell lineage and protein sequence
impacted N-glycan remodeling. N-Glycan composition can
likewise impact protein function, as is the case for IgG1, but it is
unknown how composition affects the antibody-binding func-
tion of CD16a. To test whetherN-glycan composition contrib-
utes to CD16a function, we expressed srCD16a in a HEK293S
cell line thatmakes only oligomannoseN-glycans withMan5 as
the predominant species to compare binding to HEK293F-ex-
pressed srCD16a, characterized above, with predominantly
complex-type and highly-branched N-glycans (Figs. 5 and 6)
(34).
CD16a with complex-type N-glycans bound IgG1 Fc in the
G0F glycoform with a KD of 310  100 nM and 12-fold less
affinity than CD16a with oligomannoseN-glycans (25 17 nM;
Fig. 7). Furthermore, two of the five CD16a N-glycans previ-
ously identified as positive contributors to antibody binding,
Asn-45 and Asn-162 (35–38), but not the remaining three
N-glycans at positions 38, 74, and 169, were required for the
enhanced antibody binding by CD16a displaying oligomannose
N-glycans. Removing CD16aN-glycans at positions 45 and 162
by Asn to Gln mutations abolished enhancement from the oli-
gomannoseN-glycans. These data indicate that composition of
the Asn-45 and Asn-162 CD16a N-glycans impact function.
NMR of different srCD16a N-glycoforms
Our laboratory previously observed that different IgG1 Fc
N-glycoforms led to different CD16a binding. These changes
correlated with differences in cross-peak positions observed
with solution NMR spectroscopy, and these differences
reflected changes in secondary structure for one IgG1 Fc loop
(39). We applied a similar approach and incorporated selective
backbone 15N labels into Tyr, Lys, and Phe residues to probe
whether N-glycan composition affected 1H-15N heteronuclear
single quantum coherence (HSQC) spectra of srCD16a. The 26
Tyr, Phe, and Lys residues are evenly distributed throughout
both CD16a extracellular domains. We expect changes in peak
positions as these amino acid typeswill reflectCD16a structural
changes in amanner analogous to characterizing ligandbinding
through NMR cross-peaks that change position during a titra-
tion. Indeed, a spectrum of srCD16a expressed in HEK293S
cells with oligomannoseN-glycans showed different cross-peak
positions than srCD16a with complex-type N-glycans (Fig. 8).
The largest deviations appeared in the center of the spectrum.
We observed 24 peaks, which is close to the 26 expected, and of
these, eight showed different cross-peak positions in the two
spectra with a combined 1H/15N chemical shift perturbation
for each peak of0.04 ppm as calculated with Equation 2. Fur-
thermore, one peak present in the spectrum of CD16a with
complex-type N-glycans was absent in the spectrum of CD16a
with oligomannose N-glycans, and two peaks appeared in the
spectrumof the oligomannose form. It is important to note that
only two of the 26 labeled residues are within five amino acid
residues, by primary sequence, fromN-glycosylation sites, indi-
cating extensive regions of the protein are affected byN-glycan
composition. This result is substantially different from hIgG1
Fc, where changes are limited to a single loop and not observed
throughout the protein (39).
Discussion
A high percentage of oligomannose and hybrid structures, as
well as biantennary forms constituting the largest subgroup of
the complex-type species, characterize the CD16a N-glycans
from primary human NK cells and indicate restricted pro-
cessing compared with many serum proteins. This limited pro-
cessing of NK cell CD16a N-glycans stands in stark contrast to
N-glycans from recombinant CD16a with highly-modified and
highly-branched carbohydrate structures. Furthermore, we
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provide clear evidence thatN-glycan composition impacts anti-
body binding: CD16a modified with minimally processed oli-
gomannose N-glycans bound IgG1 Fc with 12-fold greater
affinity than CD16a with a mixture of highly-processed
N-glycans.
Recombinant CD16a is often used to characterize antibody-
binding affinity in many reports, including some of our own,
due to practical considerations that include isolating sufficient
material for in vitro studies. The differences in N-glycan com-
position from these different sources highlight the need to
describe and develop the tools to mimic native source-specific
composition in studies of receptor function.N-Glycan compo-
sition is a neglected component of eukaryotic biology, particu-
larly in the context of cell-surface proteins, because access to
primarymaterials is limited, and the absolute mass of each spe-
cific receptor on a cell surface is very low (we estimate20–40
fg CD16a/NK cell). Furthermore, detailed studies linking
N-glycan composition with function are challenging and like-
wise represent a barrier to a complete characterization of
N-glycan roles in protein function. The characterization pre-
sentedhere provides a detailed description of these variables for
CD16a from NK cells. N-Glycosylation of CD16a was targeted
due to its relevance in mAb therapy, but the other Fc  recep-
tors are heavily glycosylated. This approach can be used to
characterize N-glycosylation profiles of other Fc  receptors
from primary human tissues.
The relatively limited distribution of migration rates for NK
cell CD16a in polyacrylamide gels and the bias towardN-glyco-
forms with restricted processing were striking in comparison
with frCD16a from HEK293F cells and indicate cell type-spe-
cific differences inN-glycan processing. Both frCD16a and NK
cell CD16a were coexpressed with a coreceptor that is required
for localization to the cell surface. Differences in primary struc-
ture do not account for the observed differences in N-glycan
processing: the CD16a polypeptide sequence and the presence
of the coexpressed Fc  receptor -chain were the same in both
NK cells and that used in HEK293F cells to express frCD16a.
Cell type-specific differences in the glycosylation of a specific
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protein are known (40–44) and are justifiable given the com-
plexity of gene expression and activity for glycan-processing
enzymes in different tissues (45–50).
Changes in receptor function resulting from limited N-gly-
can processing were mirrored by changes in a 2D spectrum of
[15N]Lys/Tyr/Phe-labeled CD16a (Figs. 7 and 8). The magni-
tude of peak shifts and the extent of peaks experiencing shifts in
CD16a are comparable with analyses of proteins that experi-
ence a conformational rearrangement upon ligand binding. In
the latter example, ligand docking stabilizes a specific protein
conformation. Surprisingly, CD16a N-glycan composition
imposed a similar conformational adjustment that was experi-
enced by a large number of backbone amides, indicating that
specific features of the N-glycans interact with residues on the
polypeptide surface. Our group recently described the forma-
tion of intramolecular interactions between the polypeptide
and N-glycans at Asn-45 and Asn-162 (38). N-Glycans at these
positions likely differentially impact protein conformation,
based on N-glycan composition at each site. Thus, the CD16a
N-glycans do not behave as largely inert modifications, but
rather they interact with polypeptide residues tomodulate pro-
tein function. The IgG1 Fc N-glycan composition also impacts
receptor binding through intramolecular interactions (15, 39,
51, 52).
Numerous prior studies focused on the modulation of
CD16a affinity by IgG N-glycan composition. This wealth of
information on IgG N-glycosylation is due primarily to the
availability of IgG; here, we focused on the effect of CD16a
N-glycosylation on antibody binding. The observation that
CD16a N-glycosylation affects binding affinity, potentially to a
greater extent than IgG, makes CD16a N-glycosylation an
important aspect of immune system functionwith the potential
for clinical implications. There are two important limitations to
this study. 1) The restricted donor demographic variability
could mask potential N-glycan composition variability present
in the larger population. 2) It is currently unclear whether
changes to CD16a N-glycan composition that increase anti-
1
10
100
1000
(293F) (293S)
wt N38Q/
N74Q/
N169Q 
N45Q/
N162Q
K
D
 (n
M
)
0
100
200
300
0 200 400 600 800
0 nM
31.25 nM
62.5 nM
125 nM
250 nM
500 nM
1000 nM
0
100
200
0 750 1500
1.25 nM
2.5 nM
5 nM
10 nM
20 nM
30 nM
40 nM
50 nM
Time (s)
Time (s)
In
te
ns
ity
 (a
rb
)
In
te
ns
ity
 (a
rb
)
A
B
CsrCD16a + complex-type N-glycans
srCD16a + 
oligomannose N-glycans
(293F) (293S) (293F) (293S)
Figure 7. CD16a N-glycan composition affects IgG1 Fc binding. A and B, representative SPR sensograms for IgG1 Fc with an agalactosyl core-fucosylated
complex-type biantennary N-glycan (G0F) binding to recombinant CD16a with complex-type N-glycans (A) or oligomannose N-glycans (B). C, summary of
dissociation constants for CD16a variants. Material was expressed either with HEK293F cells to synthesize primarily complex-type N-glycans (red bars) or with
HEK293S cells to synthesize only oligomannose N-glycans (green bars). Values represent the average of at least two independent experiments, and error bars
are the maximum error of the fitting.
78910
¹H (ppm)
115
120
125
130
¹5
 
N
 (p
pm
)
[15N-Lys,Tyr,Phe]-srCD16A
complex-type
N-glycans
oligomannose
*
*
†
Figure 8. CD16a N-glycan composition impacts polypeptide structure.
Select backbone amide cross-peaks observed in an HSQC experiment using
CD16a expressed with either complex-type (red contours) or oligomannose
(black contours) N-glycans. One peak present in the spectrum of CD16a with
complex-typeN-glycansbut absent in theoligomannose form is indicated (†).
Two peaks appearing in the spectrumwith oligomannoseN-glycans are indi-
cated (*).
N-Glycans fromNK cell CD16a
3484 J. Biol. Chem. (2018) 293(10) 3477–3489
 at IO
W
A
 STA
TE U
N
IV
 on February 18, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
body binding in SPR experiments enhance NK cell response.
Moreover, CD16a-expressing cells, including NK cells, are
involved with multiple pathologies (53–56). Therefore, this
information regarding specificNKcellN-glycans onCD16a can
be applied to probe the connection between patient-specific
changes in autoimmune conditions, malignancy, or infection.
Experimental procedures
All materials were purchased from Sigma unless noted
otherwise.
Cell isolation
NK cells were isolated from leukocyte reduction filters (LRS
filters), obtained from LifeServe (Ames, IA) and DeGowin
Blood Centers (Iowa City, IA), after the plateletpheresis proce-
dure. Donors signed consent forms permitting the use of
donated blood products for research purposes. We do not
directly enroll donors because we obtain materials from the
LifeServe and DeGowin Blood Centers. Cell isolation proce-
dures were performed within 3 h of the time the donor com-
pleted the apheresis procedure. NK cells were isolated by neg-
ative selection using the RosetteSep Enrichment Mixture
following the recommendedprotocol (StemCell Tech)with the
following minor changes: LRS filters were drained into a sterile
50-ml tube, and the contents were diluted to 30 ml using PBS
with 2% IgG-depleted FBS. The cell suspension was then split
into 2 15-ml aliquots, and each was mixed with 750 l of the
negative selectionmixture. After a 20-min incubation, the steps
mentioned in the protocol were followed. Contaminating
erythrocytes were then removed by incubating the cells with
erythrocyte lysis buffer (155 mM ammonium chloride, 12 mM
sodium bicarbonate, and 0.1 mM EDTA, pH 7.4) for 10 min at
room temperature. Finally, cells were counted, and viability was
analyzed with trypan blue and then frozen at 80 °C. The
CD16a allotype was determined by sequencing cDNA corre-
sponding to CD16a (cDNA isolation is described below under
the “Recombinant expression”; Iowa State University DNA
Facility).
Flow cytometry
NK cells were first blocked with 5 g of hIgG1 (Athens
Research and Technology) before incubation with primary
antibodies. For each flow cytometry experiment, 5  105 NK
cells were stained with primary antibody for 40 min in the dark
on ice, including 2g/mlmIgG2a anti-hCD56 (MEM-188, Bio-
Legend) and 2g/ml mIgG1 anti-hCD16 (3G8) or isotype con-
trols, mIgG1 (Research and Diagnostics Systems) and mIgG2a
(BioLegend). The cells werewashedwith 2 2ml of phosphate-
buffered saline, 0.05% sodium azide by centrifuging at 600 g
for 8 min, and removing the supernatant after each centrifuga-
tion. Fluorophore-conjugated secondary antibodies were
added, including anti-mIgG1-APC (RMG1–1, BioLegend) and
anti-mIgG2a-PE (RMG2a-62, BioLegend), and incubated on
ice for 40 min. Cells were fixed in 1% paraformaldehyde before
loading them onto a BD FACSCanto (BD Biosciences). For cell
purity assessment, NK cells were gated in the side and forward
scatter plot to exclude cell debris and cells (primarily erythro-
cytes) smaller than lymphocytes. Gating of double-stained cells
was determined by comparing with the fluorescence intensity
of the negative (no primary) control. Isotype controls consis-
tently showed no positive staining for either primary antibody
for the first 15 NK cell isolations performed from donors of
both gender and a wide age range.
Anti-hCD16 expression and purification
Open reading frames encoding the anti-hCD16 mouse IgG1
(3G8) heavy and light chainswere synthesized (IDT). The heavy
chain sequence was cloned into pGEef1Puro vector (provided
by Dr. Kelley Moremen, University of Georgia) using the Gate-
way cloning system (Life Technologies, Inc.). The flanking attB
sites for gateway cloning of heavy chain were included in the
synthesized heavy chain gene. The transfer of gene to final
pGEef1Puro vector was performed in a two-step gateway reac-
tion following the manufacturer’s protocol with pDONR221
(Life Technologies, Inc.) as the intermediate vector. The light
chain sequence was cloned into the pGEN2 vector using the
NotI and HindIII restriction sites (57).
The 3G8monoclonal antibodywas generated by cotransfect-
ingHEK293F cells with 3g/ml pGEef1Puro/(heavy chain) and
1.5g/ml pGEN2/(light chain) as described (57). Antibody was
secreted into the medium, adsorbed to a protein A-Sepharose
fast flow resin (GEHealthcare), and elutedwith 100mMglycine,
pH3.0, followedby immediate neutralizationwith 33%1MTris,
pH 8.0. Purified antibody was washed to replace the buffer with
a buffer containing 25mMMOPS, 100mM sodium chloride, pH
7.2, and then coupled to AminoLink aldehyde-functionalized
agarose beads at 1 mg/ml of resin according to the product
protocol (Thermo Fisher Scientific).
Antibody used to immunoprecipitate CD16a for N-glycan
analysis differed in two important ways. First, the mouse IgG1
Fc region was replaced with human IgG1 Fc. Second, this chi-
meric antibody was treated with EndoS to remove the Fc N-
glycan; 3G8 contains no N-glycosylation sequon in the Fab
domains. EndoS was expressed in E. coli using a deposited plas-
mid andpurified as described (AddGene). EndoSwas incubated
with 3G8 in 20 mM MOPS, 100 mM NaCl, pH 7.2, at a 1:50
(EndoS/3G8) molar ratio for 18 h at room temperature. The
digestionwas assessed by resolving the proteinwith SDS-PAGE
and staining with Coomassie Blue. Glutathione beads were
incubatedwith 3G8 andGST-EndoS to remove theGST-EndoS
before coupling antibody to agarose beads.
Recombinant CD16a expression
The soluble extracellular fragment of CD16a (srCD16a) was
prepared as a recombinant GFP-fusion protein and cleaved
with tobacco etch virus protease as described previously using
HEK293F cells (15). Open reading frames encoding the full-
length recombinant CD16a protein (frCD16a) and the Fc 
receptor subunit  (-chain) were cloned from cDNA obtained
fromNK cells andmonocytes, respectively. Total RNAwas iso-
lated from 10 106 monocytes (prepared with negative selec-
tion, Stem Cell Tech) and 5  106 NK cells using the TRIzol
reagent following the manufacturer’s protocol (Thermo Fisher
Scientific). A high capacity RNA to cDNA kit (Applied Biosys-
tems) was used to reverse-transcribe 500 ng of RNA from each
cell type and amplified with AccuPrime Pfx DNA polymerase
N-Glycans fromNK cell CD16a
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(Life Technologies, Inc.) to generate full-length cDNA. Primers
pairs for frCD16a were 5-cagcggccgccCAGTGTGGCATCA-
TGTGGCAG and 5-ggatccaagcttTTTGTCTTGAGGGTCC-
TTTCT containing NotI and HindIII sites, respectively.
Similarly, two primers 5-gaattcCTCCAGCCCAAGATGAT-
TCCAG and 5-ggatcctcaCTACTGTGGTGGTTTCTCATGC
with EcoRI and BamHI sites, respectively, were used to amplify
genes for -chain. Primers were designed to include the native
signal sequence form both genes. Both PCR fragments were
cloned into pGEM-TEasy vectors following themanufacturer’s
guidelines (Promega). Full-length CD16a was subcloned into
pGEN2 vector using the NotI and HindIII restriction sites. The
-chain was subcloned into pGEef1Puro vector using the
EcoRI and BamHI restriction sites. pGEN2-frCD16a and
pGEef1Puro--chain vector were cotransfected in a 1:2 mass
ratio into the HEK293F cell line as described (57). HEK cells
were transfected at a density of 3.0  106 cells ml1 with a
viability of 96%. Expressions usually proceeded for 5 days or
until cell viability fell below 50%. Typical yields for srCD16a
were 0.2mg proteinml1 culturemedium.Cell-surface expres-
sion of CD16a in HEK293F cells was confirmed by flow cytom-
etry using the anti-CD16mIgG1 (3G8) antibody before freezing
the cell pellets at80 °C
CD16a immunoprecipitation
These methods were adapted from a previously published
protocol to achieve a preparative scale purification (30). NK
cells or HEK293F cells expressing full-length CD16a were lysed
by resuspending the frozen pellet in ice-cold lysis buffer (100
mMTris, 100mM sodium chloride, 5 mM EDTA, 5mM oxidized
glutathione, 10 M potassium ferricyanide, 1 mM 4-(2-amino-
ethyl)benzenesulfonyl fluoride, 10 mg/ml dodecyl maltoside,
pH 8.0) with 200 l added for every 1  107 cells by repeated
pipetting, followed by a 20-min incubation on ice. Cell debris
was removed by centrifugation at 10,000 g for 10 min at 4 °C.
Supernatant was incubated for 1 h at 4 °C on a rocker with 5 l
of protein G-Sepharose (Sigma) per 200 l of lysate. Protein
G-Sepharose was removed by centrifuging the lysate at 500 g
for 5 min. The recovered supernatant was sonicated in a bath
sonicator for 1 min, followed by freezing at80 °C, and slowly
thawed on ice. 3G8-coupled agarose beads (20 l) were added
per 200 l of NK cell lysate and incubated for 1 h at 4 °C on a
rocking shaker. The resin was centrifuged at 500 g for 5 min
and washed twice with lysis buffer using 10 times the resin
volume for each wash followed by two washes with 50mMTris,
100mM sodium chloride, pH 8.0, and final twowashes with 100
mM ammonium carbonate, pH 8.0. CD16 was eluted in 45:55:
0.1 (HOH/acetonitrile/TFA) by centrifugation through a spin
column to retain the resin.
PNGase F digestion of CD16a
PNGase F digestion of CD16a isolated from NK cells was
performed per the manufacturer’s protocol. NK cell CD16a
bound to 3G8-agarose was boiled at 100 °C for 10 min in 1
denaturing buffer (0.5% SDS, 40mM dithiothreitol) followed by
addition of GlycoBuffer2 and 10%Nonidet P-40 to the reaction
(New England Biolabs). After adding 1 l of PNGase F, the
sample was incubated at 37 °C for 4 h, and the reaction was
stopped by heating at 95 °C for 5 min after the addition of 1
volumeof 2 SDS-PAGE sample buffer containing 10%-mer-
captoethanol. A control reaction with CD16a was treated in an
identical manner, except without the addition of PNGase F.
Western blotting
Eluted protein was resolved on an SDS-polyacrylamide gel
(12% unless mentioned otherwise) and transferred onto a poly-
vinylidene difluoride membrane using the one-step electro-
blotting system (Thermo Fisher Scientific). Themembranewas
blocked with 5% dry milk in TBS Tween 20 (TBST) buffer for
1 h at room temperature. All incubations and washes were per-
formedon anorbital shaker. Following blocking, themembrane
was stained for 18 h at 4 °C with anti-hCD16 (Research and
Diagnostic Systems, 0.1 g/ml) in 5%milk in TBST buffer. The
blot was washed four times with TBST buffer for 5 min and
stained with secondary anti-goat HRP (Research and Diagnos-
tic Systems, dilution 1:2000) in 5%milk inTBSTbuffer for 1 h at
room temperature. After washing four times, the blot was
imaged on a ChemiDoc XRS Image system (Bio-Rad) using
the ECLWestern blotting substrate (Thermo Fisher Scientific).
Peptidemass spectrometry
CD16 for peptide sequencingwas isolated as described under
“CD16a immunoprecipitation.” In the first instance, CD16a
was excised from 12% SDS-PAGE at the same size as detected
by the Western blotting detection system. The gel was sub-
jected to standard in-gel trypsin digest on the Molecular
Dynamics ProGest (Genomic Solutions) instrument. The sam-
ple was then dried down and resuspended in 1.25 l of buffer B
(0.1% formic acid in acetonitrile). In the second instance, pep-
tides retained by the C18 Sep-Pak during the isolation ofN-gly-
cans from donor 3 (following treatment with PNGase F and
trypsin) were eluted with isopropyl alcohol and lyophilized.
Both samples were resuspended in 23.75 l of buffer A (0.1%
formic acid in water). Next, the sample was mixed, spun down,
and put into a sample vial. The vial was then loaded onto a
Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometer
(Thermo Fisher Scientific) equipped with a 1260 HPLC (Agi-
lent) and C18 column and eluted as described previously (58).
Peaks fromMS1 andMS2 spectrawere searchedwith themam-
malian Mascot database server. Raw data were processed with
Sequest HT (Version 1.17) andMascot 2.2.07 (Matrix Science).
The peptides identified were then analyzed using Proteome
Discoverer Version 2.1 software (Thermo Fisher Scientific).
Procainamide labeling of PNGase F-released N-glycans
Following heat denaturation of CD16a for 5min at 90 °C, 1l
of sequencing grade trypsin (Promega; 1 mg/ml in 50 mM
ammonium carbonate, pH 8.0) was added and incubated at
37 °C for 18 h after mixing. The trypsinized sample was again
incubated at 90 °C for 5min to denature the trypsin, followed by
cooling for 5 min on ice. PNGase F (1 l; glycerol-free; New
England Biolabs) was then added to the sample and incubated
at 37 °C for 18 h. A Hypersep C18 column (Thermo Fisher
Scientific) was washed three times with 1 ml of methanol and
then three times with 1 ml of 5% acetic acid. Free N-glycans
were isolated by applying the sample, diluted in 5% acetic acid,
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over the C18 column and collecting the flow- through. Wash
fractions (3 1 ml) of 5% acetic acid were collected in the same
tube, then frozen, and lyophilized. The lyophilized sample was
then resuspended in 200l of double-distilled water by vortex-
ing and transferred to a microcentrifuge tube, frozen, and
lyophilized again. The sample was then resuspended in 10l of
water. A stock solution containing 2 M sodium cyanoborohy-
dride, 1 M procainamide, and 50% acetic acid (10 l) was added
to the sample, mixed, and incubated for 18 h at 37 °C. The
samplewas then lyophilized and resuspended into 10l of dou-
ble-distilled water.
Hydrophilic interacting chromatography-mass spectrometry
The HPLC instrument used was an Agilent 1260 HPLC with
an Acquity UPLC Glycoprotein BEH Amide, 300 Å, 1.7-m
HILIC column (Waters). The lyophilized procainamide-la-
beled glycan samples were resuspended in double-distilled
water, and 9 l was injected onto the column prewashed with
25% Solvent A (0.1% formic acid and 0.01% TFA in double-
distilled water) and 75% Solvent B (0.1% formic acid and 0.01%
TFA in acetonitrile) with a flow rate of 0.1 ml/min. The glycans
were then eluted by a gradient at 0.1 ml/min flow rate unless
otherwise indicated; 0.5–10.5 min (gradient from 25 to 35% A),
10.5–40.5 min (a gradient from to 35 to 50% A), 40.5–41.5 min
(50 to 100% A), 41.5–43.5 min (100% A), 46.5–47 min (25% A,
75% B) at 0.05 ml/min and 47–60 min (25% A, 75% B) at 0.1
ml/min at 45 °C. Upon elution, the samples were coupled in-
line to a Q ExactiveTM Hybrid Quadrupole-OrbitrapTM mass
spectrometer (Thermo Fisher Scientific). The mass spectrom-
eter (scan range 266.7–4000m/z) subjected ions to higher-en-
ergy collisional dissociation (HCD) fragmentation (scan range
of 200–2000 m/z) at a normalized collisional energy of 27 eV.
In-between samples, identical chromatography and MS analy-
ses were performed following an injection of water. These were
scanned to ensure no carryover between samples. Sample spec-
tra were then analyzed by converting the RAW spectra file to
text format with MSConvert. The output was then scanned
against a list of N-glycans calculated for singly, doubly, and
triply charged procainamide-derivatized species to identify
peaks with corresponding retention times and intensities.
These matches were then validated manually by analyzing the
RAW file in XCaliber (Thermo Fisher Scientific). Averagemass
error for each data set was calculated according to Equation 1.
error

1
nm/zncalcm/znobs
n
(Eq. 1)
IgG1 Fc binding assays by SPR
Expression, purification, and preparation of IgG1 Fc in the
G0F glycoform and CD16a-binding analyses by surface plas-
mon resonance were performed as described previously (52).
Dissociation constants were fitted to the equilibrium response
units for each condition.
NMR spectroscopy
Isotope-labeled srCD16a expression and NMR experiments
were conducted as described previously (39). Chemical shift
perturbations (CSP) were calculated using Equation 2.
CSP 		1H
2
 16		15N
2 (Eq. 2)
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